Australia Markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
24.39+0.42 (+1.75%)
At close: 04:00PM EDT
24.39 0.00 (0.00%)
After hours: 04:08PM EDT

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048

Full-time employees285

Key executives

NameTitlePayExercisedYear born
Dr. N. Anthony Coles Jr., M.P.H.Exec. Chairman & CEO1.01MN/A1960
Mr. Abraham N. Ceesay M.B.A.Pres776.64kN/A1978
Mr. Mark BodenraderInterim CFO, VP of Fin. & Chief Accounting Officer440.89kN/A1973
Mr. Scott M. Akamine J.D.Chief Legal Officer & Corp. Sec.444.74kN/A1985
Dr. Ramiro Sanchez M.D.Chief Medical Officer716.29kN/A1961
Dr. John J. Renger Ph.D.Chief Scientific OfficerN/AN/A1969
Mr. Matthew CalistriVP of Investor RelationsN/AN/AN/A
Mr. Kenneth A. DiPietroChief HR OfficerN/AN/A1959
Ms. Kathleen Tregoning M.A.Chief Corp. Affairs OfficerN/AN/A1971
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cerevel Therapeutics Holdings, Inc.’s ISS governance QualityScore as of 1 February 2023 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.